美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

避孕概念

2,538.91

-5.4336-0.21%

涨家数：3

跌家数：2

平家数：- -

市盈率：- -

高：2,596.63

开：2,545.80

低：2,537.54

收：2,544.35

成交量：2,358.03万

成交额：1.31亿

市值：408.35亿

流通市值：399.98亿

数据加载中...

总览新闻资讯

Dare Bioscience获ARPA-H千万美元合同支持HPV疫苗开发，关键数据预计2027年公布

梯瓦研究揭示：仅23%患有情绪障碍与迟发性运动障碍症状的年轻成人获正式TD诊断，尽管影响广泛

Dare Bioscience启动Dare-HPV二期研究，针对无FDA批准疗法的高危持续性HPV感染

Veru发布2026财年第二季度财报及2B期高原临床试验进展

Dare Bioscience研究中12%参与者因阴道异味退出，较2025年7月下降5%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4584/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"避孕概念","latestPrice":2538.9136,"timestamp":1779479999999,"preClose":2544.3472,"halted":0,"volume":23580316,"delay":0,"changeRate":-0.002136,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-5.433594,"latestTime":"05-22 16:00:00 EDT","open":2545.7969,"high":2596.6267,"low":2537.5366,"amount":131492535.546006,"amplitude":0.023224,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779802200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.979722,"peRate":27.20251,"turnoverRate":0.015506,"increases":3,"decrements":2,"flats":0,"marketCap":40834947304,"floatMarketCap":39997622874},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2596.6267,"amplitude":0.023224,"preClose":2544.3472,"low":2537.5366,"pbRate":"4.979722","latestPrice":2538.9136,"volume":23580316,"delay":0,"open":2545.7969,"prevYearClose":2379.9924,"prevWeekClose":2538.9136,"prevMonthClose":2602.58,"prevQuarterClose":2236.9697,"fiveDayClose":2550.0078,"twentyDayClose":2278.3528,"sixtyDayClose":2515.2932,"secType":"PLATE","market":"US","turnoverRate":0.015506,"peRate":27.20251,"marketCap":40834947304,"floatMarketCap":39997622874,"timestamp":1779479999999,"nameCN":"避孕概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1167212099","title":"Dare Bioscience获ARPA-H千万美元合同支持HPV疫苗开发，关键数据预计2027年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1167212099","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167212099?lang=zh_cn&edition=fundamental","pubTime":"2026-05-18 20:01","pubTimestamp":1779105690,"startTime":"0","endTime":"0","summary":"生物制药公司Dare Bioscience宣布，其针对人乳头瘤病毒的疫苗开发项目已获得美国卫生高级研究计划局一项价值1000万美元的合同支持。根据规划，该疫苗项目的关键临床数据预计将于2027年公布。此次资金注入将加速DARE-HPV疫苗的研发进程，涵盖临床前研究及后续临床试验阶段。若研发进展顺利，该疫苗有望为预防HPV相关疾病提供新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","DARE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118285288","title":"梯瓦研究揭示：仅23%患有情绪障碍与迟发性运动障碍症状的年轻成人获正式TD诊断，尽管影响广泛","url":"https://stock-news.laohu8.com/highlight/detail?id=1118285288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118285288?lang=zh_cn&edition=fundamental","pubTime":"2026-05-18 20:01","pubTimestamp":1779105679,"startTime":"0","endTime":"0","summary":"一项由梯瓦制药进行的研究发现，在患有情绪障碍并表现出迟发性运动障碍症状的年轻成人群体中，仅有23%的人获得了正式的TD诊断。这一数据凸显出，尽管该疾病的影响广泛存在，但在临床实践中仍存在显著的诊断不足问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","TEVA","BK4588","LU1983299246.USD","LU2324357040.USD","BK4559","BK4596","BK4585","BK4557","BK4566","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194848300","title":"Dare Bioscience启动Dare-HPV二期研究，针对无FDA批准疗法的高危持续性HPV感染","url":"https://stock-news.laohu8.com/highlight/detail?id=1194848300","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194848300?lang=zh_cn&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105638,"startTime":"0","endTime":"0","summary":"Dare Bioscience已启动其新型药物疗法Dare-HPV的二期临床研究，该疗法旨在治疗目前尚无美国食品药品监督管理局批准疗法的高危持续性人乳头瘤病毒感染。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4584","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176456050","title":"Veru发布2026财年第二季度财报及2B期高原临床试验进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1176456050","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176456050?lang=zh_cn&edition=fundamental","pubTime":"2026-05-13 18:33","pubTimestamp":1778668401,"startTime":"0","endTime":"0","summary":"Veru Inc.近日公布了其2026财年第二季度的财务业绩，并同步更新了其处于2B期阶段的高原临床试验的最新进展。公司本季度的财务表现与关键临床项目的推进情况，共同勾勒出其当前的发展图景与未来的战略重心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4584","BK4007","VERU","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109935684","title":"Dare Bioscience研究中12%参与者因阴道异味退出，较2025年7月下降5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109935684","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109935684?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 20:02","pubTimestamp":1778587347,"startTime":"0","endTime":"0","summary":"Dare Bioscience最新数据显示，一项临床研究中因阴道异味而退出的参与者比例降至12%，这一数字较2025年7月记录的17%下降了5个百分点。这一变化反映了公司在产品耐受性方面的潜在改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DARE","BK4584"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}